Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update

Newsroom Latest from Alvotech Investor news Request email alerts Stay current with Alvotech news and developments. Receive investor announcements and updates as they go live. SEC Filings Events News About Us Media Center Careers Newsroom Contact us Terms of Use Privacy Policy Cookie Policy Alvotech 2025. All rights reserved. Newsroom Contact us FAQ Íslenska Company For investors Biosimilars Corporate Sustainability Careers Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 Tag All Company Announcement Financial Reports Inside information Managers’ Transactions Company Announcement 21 August 2026 Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets REYKJAVIK, ICELAND (August 21, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,... Financial Reports 19 August 2026 Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar... Company Announcement 10 August 2026 Alvotech to Report Financial Results for H1 2026 REYKJAVIK, ICELAND (August 10, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for... Company Announcement 29 July 2026 Alvotech announces successful closure of FDA inspection of manufacturing facility REYKJAVIK, ICELAND (July 29, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for... Managers’ Transactions 03 July 2026 Transactions of Managers and Closely Associated Persons Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the pledging... Company Announcement 01 July 2026 Alvotech further strengthens liquidity by securing term loan facility of $75 million $75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset ManagementFollows recent $165m equity raise strengthening cash positionIncluding equity financing and... Managers’ Transactions 22 June 2026 Transactions of Managers and Closely Associated Persons Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition... Company Announcement 18 June 2026 Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar... Inside information 16 June 2026 Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement REYKJAVIK, ICELAND (June 16, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar... Company Announcement 15 June 2026 Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares REYKJAVIK, ICELAND (June 15, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar... Managers’ Transactions 10 June 2026 Transactions of Managers and Closely Associated Persons Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding a transaction of managers and closely associated persons, announcing the allocation... 1 2 3 4 … 32